Decision-making tool for Spanish-speaking ovarian cancer patients
Engaging Patients in Decision Making: The Development and Pilot Testing of a Low Literacy Spanish Language Shared Medical Decision Tool for Ovarian Cancer Maintenance Therapy
This study is testing a new decision-making tool for Spanish-speaking ovarian cancer patients to help them make better choices about their maintenance therapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT06036810 on ClinicalTrials.gov |
What this trial studies
This project aims to develop a shared decision-making tool specifically designed for Spanish-speaking patients with ovarian cancer who are considering maintenance therapy. The tool will be created in a low literacy format to ensure accessibility and will be integrated into routine clinical care. The study will assess the feasibility and acceptability of this tool, as well as its effectiveness in improving the quality of decision-making among patients. A pilot study will be conducted to gather data on its impact.
Who should consider this trial
Good fit: Ideal candidates include Spanish-speaking individuals aged 18 and older with advanced stage high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are eligible for maintenance therapy.
Not a fit: Patients who are not Spanish-speaking or those who are unable or unwilling to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this tool could empower Spanish-speaking patients to make informed decisions about their maintenance therapy for ovarian cancer.
How similar studies have performed: Other studies have shown success in using shared decision-making tools for various conditions, indicating potential for this approach in ovarian cancer care.
Eligibility criteria
Show full inclusion / exclusion criteria
Study population: This study will enroll patients and clinical providers. Inclusion criteria: Patients • Eligible patients must be: 1) individuals ≥ 18 years with advanced stage high grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are receiving or have completed platinum-based chemotherapy for ovarian cancer and are potentially eligible to receive maintenance therapy; 2) able to understand, speak or read in Spanish. Exclusion criteria: Patients • Inability or unwillingness to sign informed consent Inclusion criteria: Clinicians • Eligible clinicians will include: 1) MD Anderson gynecologic oncologists and advanced practice providers who practice at the Houston Area Locations (HALs), MD Anderson Cancer Center, or our county safety net hospital, The Harris Health System (LBJ Hospital). Exclusion criteria: Clinicians • Inability or unwillingness to sign informed consent
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Larissa Meyer, Meyer — M.D. Anderson Cancer Center
- Study coordinator: Larissa Meyer, M D
- Email: Lmeyer@mdanderson.org
- Phone: (713) 745-0973
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.